PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers - Wikidata - awgldk - TriplyDB

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

http://www.wikidata.org/entity/Q42702906

about

Novel Molecular Markers for Breast Cancer Targeting CDK4 and CDK6: From Discovery to Therapy PRMT5-Mediated Methylation of NF-κB p65 at Arg174 Is Required for Endothelial CXCL11 Gene Induction in Response to TNF-α and IFN-γ Costimulation PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.Aberrant expression of cyclin D1 in cancer.The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.The Fanconi anemia pathway controls oncogenic response in hematopoietic stem and progenitor cells by regulating PRMT5-mediated p53 arginine methylation.Post-translational control of transcription factors: methylation ranks highly.CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape.A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.Cyclin D1, cancer progression, and opportunities in cancer treatment.PRMT5-dependent p53 escape in tumorigenesis.Anguilla japonica lectin 1 delivery through adenovirus vector induces apoptotic cancer cell death through interaction with PRMT5.A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival.Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.Targeting protein arginine methyltransferase 5 in disease.The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.Histone phosphorylation by TRPM6's cleaved kinase attenuates adjacent arginine methylation to regulate gene expression.Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening.CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy.Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.

P2860

Q26753160-32CF0007-F0FB-4E18-8A1E-D3A8E3EF9CDB Q28082912-6209D8B6-BCDF-4064-A561-7B75CD6F71B9 Q28550383-E6979EA4-820E-4675-A081-E5A0C57AF465 Q36224716-FDFD8ADD-D9FF-44BA-9CAE-142FAD1A0E61 Q37580471-C218CEF4-D0CA-40EF-AA6F-6A9406864C74 Q37588076-2DCF8037-8CED-4CEB-A5FE-4169F1C5C489 Q37625481-73B17001-36EE-41F5-AD3F-9CDC186BEE93 Q37644979-36695BC8-AE8C-4275-AAB1-8798049EE043 Q38592178-F90A0674-01CA-42EA-99E3-43E446D1851E Q38616175-D81D8C6C-8058-45DD-AD10-231E3B28EB8A Q38843250-74145FD2-8A79-4B37-8934-EC0D69D0D361 Q38857167-B9036A2D-132A-4AAF-94F5-AB8B9A3212A3 Q38970431-ED81427F-D9A2-4A1F-BC29-A67244A5C411 Q41893763-7CB5041B-D34C-44F4-9003-FFB25055A5F2 Q45884221-E82A1D29-CD55-4CA0-A2D7-CC8C0B8EB28F Q46244712-9B4A8ED0-6815-4804-9E91-228577E8170A Q47381020-BA59027F-B7CE-448A-87FF-ABCCEA196A24 Q47404539-47824A40-B85F-41A1-AB85-E9DCA94EB549 Q47748522-CB4CF40C-37A3-44AE-A4C2-BC4BE7B75975 Q47981534-B5641074-E3B0-42D9-9A49-1E138FE4E093 Q50915851-469947E2-E6A6-4538-B398-BD70B2E71706 Q52353697-DC8A9E22-F4B7-44AE-BBA5-095031BA13A3 Q55093730-758A29A7-8823-475E-816C-642A5067CD77 Q55106924-D7FC2643-4EBB-4AB8-891E-26FDB3384C46 Q55512206-6A9C3EE9-3566-42ED-87BB-74BFD53915CE

P2860

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

http://www.wikidata.org/entity/Q42702906

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

@en

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

@nl

type

label

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

@en

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

@nl

prefLabel

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

@en

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

@nl

P1433

Q42702906-EE44CF78-433F-4836-8627-0D9C9687F92F

P1476

Q42702906-3F3DE1BA-1C65-412F-A2A1-01E509568952

P2093

Q42702906-08800F41-1025-4730-995D-0255FA22D607

Q42702906-30999709-190C-45AD-8035-76025FF8111D

Q42702906-4058875A-AAA6-4C10-AECB-24ADC681A85A

Q42702906-457990D3-4DF1-4652-AD3E-F7A72B561A96

Q42702906-54D7ABED-9BC9-44C4-B4B9-66ED90E23DBF

Q42702906-63842CFB-A2EB-43F3-BD0F-C2B3783E3DEB

Q42702906-AEB41AED-7942-47BD-85A7-FFA1A5A9FFD8

Q42702906-D0F667DC-71BF-4A2B-ABC6-E1361AB83697

Q42702906-DF7B6C5C-AFAA-472B-802D-EE01CE8D7D04

Q42702906-E2B1427A-D500-401B-8F02-F58A5A53F921

P2860

Q42702906-016CD3BB-D57B-4E45-937A-B7DE21E81453

Q42702906-02844910-12F8-46F8-AE86-9F6D0802B3AD

Q42702906-0EC1319D-2B4E-4C33-B57E-00DA0E1E5249

Q42702906-110EB7B5-3569-43B1-B4E7-F3714ECDF78C

Q42702906-132FC307-C784-4F43-AB72-619D0A4AA26B

Q42702906-1B40382C-A439-4177-9FB1-4CA6DD815DD5

Q42702906-263ACA2B-213C-4690-9FAA-91B19A2B51EF

Q42702906-275A6CFA-2A7B-423F-8770-33F32999D2C7

Q42702906-29F9B956-2DBF-43EB-9176-9FB0D6A4253C

Q42702906-2B916326-F4EE-4342-B6D6-68271A852D05

P304

Q42702906-99B464A9-90E6-41FA-905E-1A964379B02B

P31

Q42702906-B3565840-DFFD-4347-82B6-7E3831D5BDC9

P356

Q42702906-59EF2F73-5417-46F3-9D14-957047157C7F

P433

Q42702906-4BC5AF81-BB0A-40C8-BF3E-C1A5AD2965F1

P478

Q42702906-FB503193-BA95-40C1-B53C-A8620E564A20

P577

Q42702906-EB0E2452-012B-4F5A-856D-65D8B85085BE

P698

Q42702906-27CBE3A4-FAE2-47B3-B39E-8A437893C06F

P932

Q42702906-E9E942FF-CE3B-49F2-AC37-B734511D5C33

P356

2159-8290.CD-14-0625

P1433

Cancer Discovery

P1476

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers

@en

P2093

Andres J P Klein-Szanto

http://www.w3.org/2001/XMLSchema#string

Anil K Rustgi

http://www.w3.org/2001/XMLSchema#string

Hiroshi Nakagawa

http://www.w3.org/2001/XMLSchema#string

J Alan Diehl

http://www.w3.org/2001/XMLSchema#string

Mariusz Wasik

http://www.w3.org/2001/XMLSchema#string

Nilesh Chitnis

http://www.w3.org/2001/XMLSchema#string

Shoji Natsugoe

http://www.w3.org/2001/XMLSchema#string

Yan Li

http://www.w3.org/2001/XMLSchema#string

Yi Yang

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Kita

http://www.w3.org/2001/XMLSchema#string

P2860

Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase

Arginine methylation controls growth regulation by E2F-1

Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis

Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination

Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes

Replication licensing and cancer--a fatal entanglement?

Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex

Arginine methylation regulates the p53 response

Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation

A novel cyclin encoded by a bcl1-linked candidate oncogene

P304

288-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-14-0625

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25582697

http://www.w3.org/2001/XMLSchema#string

P932

4355177

http://www.w3.org/2001/XMLSchema#string